Lower-Dose Therapy Controls HCV, Duke University Study
MedPage Today -- Hepatitis C (HCV) therapy based on low-dose peginterferon alpha-2b (Peg-Intron) achieved a sustained virologic response rate and tolerability comparable to a higher dose of alpha-2b and peginterferon alpha-2a (Pegasys), a multicenter clinical trial found.